The First FDA-Approved Cannabis Medicine Could Shut Out Other Marijuana Products
Families with epileptic children don’t want to swap what’s already working for this new med.
Meagan Patrick plays with her daughter, Addie, at their Acton home Wednesday, Dec. 4, 2013. Addie suffers from severe epilepsy, and research shows that medical marijuana can help cut down on the number of seizures the children have. Patrick is so desperate to try it for Addie, she is flying to Colorado later this month – a state that is at the forefront of research for pediatric uses of medicinal marijuana – to establish legal residency there. (Photo by Gabe Souza/Portland Press Herald via Getty Images)
Patients are concerned that changes to state laws to allow for the first cannabis-derived medication in pharmacies could limit their access to cannabis medicine at dispensaries. On Monday (June 25), the U.S. Food and Drug Administration announced their decision to approve the country’s first cannabis-derived drug. The drug, Epidiolex, comes from CBD and is designed to treat two rare forms of child epilepsy. It’s made by UK-based company GW Pharmaceuticals.
Currently, some state laws prevent any cannabis-derived drug from being sold in pharmacies. Last year, one of GW Pharmaceuticals’ affiliated companies, Greenwich Biosciences, began a lobbying campaign to change that. But it could end up changing state laws in such a way that all CBD products must get FDA approval before they’re sold. Families, interviewed by the Associated Press, are upset by this prospect as many of them have already found CBD products that work for their epileptic children and don’t want to switch over to Epidiolex.
GW Pharmaceuticals says it is not their intention to shut out other marijuana products and that they only want to make sure their medicine is accessible. FDA approvals, however, can require a long, complicated review process, making the approval of Epidiolex a historic one.
A growing body of research suggests that medical cannabis products like CBD oil can be an effective treatment for reducing seizures among patients with childhood epilepsy. Last year, the American Epilepsy Society (AES) found that CBD was effective in reducing the number of seizures that epileptic patients suffer as well as their severity. The same year, another study was published in the New England Journal of Medicine, which found that patients with Dravet syndrome experienced 40% fewer seizures after being treated with CBD oil. One systematic review of available research also concluded that medical cannabis does in fact show promise in treating childhood epilepsy.
While more research is needed on the ability of medical cannabis products to treat epilepsy, the anecdotal evidence is certainly convincing. In one case, a young boy from Northern Ireland successfully made it an entire year without experiencing a seizure after he began taking high-CBD cannabis oil. Earlier this year, a six-year-old girl with intractable epilepsy who uses CBD oil became Texas’ very first medical cannabis patient.
Right now, concerns about how Epidiolex could affect access to other, non-FDA approved cannabis medications are hypothetical. It’s yet to be seen whether these concerns will come to fruition.
The federal agency joins a community of health experts who think smoking is not a good way to consume weed.
Federal laws have to change so Epidiolex can get to market. Will it impact other CBD products?
This would transform the booming CBD market.